Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Company Deals Drug

Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising

Fineline Cube Mar 10, 2026
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential

Fineline Cube Mar 10, 2026
Company Drug

Henlius Biotech’s HLX3901 Wins NMPA Approval – First-in-Class Tetra-Specific Antibody Targets DLL3-Positive Solid Tumors

Fineline Cube Mar 10, 2026
Company Deals

Tianjin Century Kangtai Biomedical Raises Hundreds of Millions in Series A+ and B Financings

Fineline Cube Sep 20, 2023

Tianjin Century Kangtai Biomedical Engineering Co., Ltd, a China-based company, has reportedly secured hundreds of...

Company Drug

Walvax Biotechnology Receives Indonesian FDA Approval for Phase III Pneumococcal Vaccine Trial

Fineline Cube Sep 20, 2023

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced that it has received approval from...

Company Drug

Sunshine Guojian Pharmaceutical Gets NMPA Approval for SSGJ-611 Phase II COPD Study

Fineline Cube Sep 20, 2023

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG: 1530),...

Company Drug

AbbVie’s Allergan Aesthetics Secures NMPA Approval for Juvéderm VOLUMA with Lidocaine

Fineline Cube Sep 20, 2023

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced that it has received marketing...

Company Deals

Northeast Pharmaceutical Partners with Muscat Changming for Middle East Expansion

Fineline Cube Sep 20, 2023

China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has entered into an investment framework agreement with...

Company Deals

Cure Genetics and Frametact Ltd Partner on AAV Vectors for Neurological Diseases

Fineline Cube Sep 19, 2023

Suzhou-based Cure Genetics has entered into a collaboration and licensing agreement with Hong Kong’s Frametact...

Company Drug

Caliway Biopharmaceuticals’ CBL-514 Achieves Milestones in Dercum’s Disease Trial

Fineline Cube Sep 19, 2023

Taiwan-based Caliway Biopharmaceuticals, a specialist in medical aesthetics and inflammatory medicine, has announced that its...

Company Deals

BRIM Biotechnology Raises $45.8 Million in Premium Share Issue for Pipeline Expansion

Fineline Cube Sep 19, 2023

Taiwan-based BRIM Biotechnology, Inc. (TPEx 6885), a biotechnology company specializing in the development of regenerative...

Company Deals

Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round

Fineline Cube Sep 19, 2023

China’s Suzhou Acumen Biomedical Technology Co., Ltd. has reportedly raised close to RMB 100 million...

Company Medical Device

MicroPort MedBot’s SkyWalker Robot Approved for Orthopedic Surgery by NMPA

Fineline Cube Sep 19, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...

Company Drug

Zhejiang Medicine Gets NMPA Approval for NCB003 Clinical Study for Advanced Solid Tumors

Fineline Cube Sep 19, 2023

Zhejiang Medicine Co., Ltd (SHA: 600216), a China-based pharmaceutical company, has announced that it has...

Company Drug

Zelgen Biopharmaceuticals’ rhTSH Achieves Primary Endpoint in Phase III Study

Fineline Cube Sep 19, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based pharmaceutical company, has announced that its...

Policy / Regulatory

China’s CDE Proposes Removal of Ambroxol Inhalation Solution and Four Other Drugs

Fineline Cube Sep 19, 2023

The Center for Drug Evaluation has issued a notification concerning the Chemical Generic Drug Reference...

Company Drug

CSBIO’s Albenatide Shows Positive Results in Two Phase III Diabetes Trials

Fineline Cube Sep 19, 2023

Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255) has announced encouraging results from two...

Company Drug

Sandoz Receives Positive CHMP Review for Trastuzumab Biosimilar in HER2-Positive Cancers

Fineline Cube Sep 19, 2023

Sandoz (SWX: SDZ), the generic and biosimilar drug maker set to separate from Novartis (NYSE:...

Policy / Regulatory

NMPA Drafts Quality Management Norms for Online Medical Device Sales

Fineline Cube Sep 19, 2023

The National Medical Products Administration (NMPA) has issued the “Medical Device Online Sales Quality Management...

Policy / Regulatory

NMPA Seeks Comments on Medical Device Classification Draft Proposal

Fineline Cube Sep 19, 2023

The National Medical Products Administration (NMPA) has issued a notification focusing on the definition and...

Company Drug

Gilead’s Kite CAR-T Therapy Yescarta Achieves 71% CMR in Phase II Trial for R/R LBCL Patients

Fineline Cube Sep 19, 2023

Gilead’s (NASDAQ: GILD) subsidiary Kite has announced early results from a Phase II trial of...

Company Deals

Pharmanovia Bolsters Neurology Portfolio with Acquisition of Sanofi’s CNS Products

Fineline Cube Sep 19, 2023

UK-based healthcare company Pharmanovia has announced the expansion of its neurology portfolio through the strategic...

Company Deals

Tonghua Dongbao Pharmaceuticals Partners with King-Friend Biochemical on Insulin Development

Fineline Cube Sep 18, 2023

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has entered into a partnership with fellow Chinese firm...

Posts pagination

1 … 437 438 439 … 632

Recent updates

  • Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential
  • Henlius Biotech’s HLX3901 Wins NMPA Approval – First-in-Class Tetra-Specific Antibody Targets DLL3-Positive Solid Tumors
  • Qyuns Therapeutics’ QX002N NDA Accepted by NMPA – IL-17A Antibody Targets Ankylosing Spondylitis Market
  • GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value
  • FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential

Company Drug

Henlius Biotech’s HLX3901 Wins NMPA Approval – First-in-Class Tetra-Specific Antibody Targets DLL3-Positive Solid Tumors

Company Drug

Qyuns Therapeutics’ QX002N NDA Accepted by NMPA – IL-17A Antibody Targets Ankylosing Spondylitis Market

Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.